What do we know about IL-18 Normal levels less than 500 Non specific 500 to 15000 Stills (quiet) 2000 to 10000 Mas/glares 20000 and more @RheumNow #ACR25 https://t.co/ZAltAD5Q8V

#ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syndrome (LICATS) with CAR-T. - Mostly afect skin & kidneys - Med time of onset 10 days; duration 11 days -Most LICATS were mild & without sequelae @RheumNow https://t.co/EnAWL936oh

Dr. Gensler gave a fantastic talk on SpA mimics ☝️Not all IBP is axSpA - interpret in the appropriate context + imaging WOF other mimics 🔸 Sacral insufficiency fractures 🔸 Infections 🔸DISH #ACR25 @RheumNow https://t.co/7TIqyp5rYe

In a Brazilian cohort (n=791), axSpA diagnosis delay dropped from 41.7 yrs (1960s) to 1.9 yrs (2020s). Female representation rose to 50%. Non-radiographic axSpA now 16.7%. MRI and updated criteria driving earlier, more equitable recognition. Abstract#1407 @RheumNow #ACR25 https://t.co/8hIpX0a1Sa

Who talks to their neighbour? +SSA / Ro talk differently to nearby cells in #SjD #salivary #glands vs NEG Ro SjD Ro52 acts differently than Ro60 ?implications for Rx response? 🤷‍♀️ #ACR25 @RheumNow @ACRheum #Sjogren’s Abst#1684 #ACRBest! Elegant work from Sara McCoy https://t.co/UWUKAxi0UW

How many patients do you need to treat to prevent one RA conversion in at-risk individuals? APPIPRA and ALTO Interception studies, long term data Number Necessary to Treat to prevent 1 RA conversion across time: 1yr = 4 2yrs = 7 3, 4, 5 yrs = 9 6 yrs = 11 #ACR25 #ABSTRACT1678 https://t.co/GBzUJG8jVk

DYK? A bipartite ilium is a common SIJ variant. More common among women. SpA mimics involving biomechanical stress: BME & sclerosis 🔸OCI - assoc w/ multiparity, obesity 🔸Degenerative dse #ACR25 @RheumNow https://t.co/IoZepAJKJ6

So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset? ALTO study (APIPPRA continuation) 1y abatacept then follow If autoAb x5 (RF, ACPA IgG, IgA, anti-CarP, AAPA): sustained delay of RA If not: benefit only on Rx #ACR25 ABST1678 @RheumNow https://t.co/3Pc5ZLzVf6

#ACR25 Abstr#1401 Sjogren’s #SjD is definitely not a benign disease! Real world study using US database showed high disease burden within 12 mths of diagnosis (i.e. healthcare resource use). GC use was high (~50%). Better therapy is needed to improve outcomes @RheumNow https://t.co/MI3vQ5LByr

TNFi induction first year in RA leads to: - less D2T RA at 5y - more sustained remission from 10y onward - less DMARD utilization - less healthcare utilization in these real-world matched cohorts given biosimilar prices, this might be worth considering #ACR25 ABST1677 @RheumNow https://t.co/uL9nHtLkXZ